Evidence map›Paper›PMID 40806723›Full record

ArticleInternational journal of molecular sciences2025

Two Decades of Disease Evolution and Biomarker-Guided Clinical Decision Making in Metastatic Prostate Cancer.

Tatiana Erazo, Enrico Moiso, Omer Aras, Howard I Scher

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tatiana ErazoTranslational Partnership Program, Memorial Sloan Kettering Cancer Center (MSK), New York, NY 10065, USA.
Enrico MoisoTranslational Partnership Program, Memorial Sloan Kettering Cancer Center (MSK), New York, NY 10065, USA.
Omer ArasDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Howard I ScherTranslational Partnership Program, Memorial Sloan Kettering Cancer Center (MSK), New York, NY 10065, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Despite significant advances in prostate cancer treatment over the past two decades, metastatic castration-resistant prostate cancer (mCRPC) remains incurable. We present the case of a patient with aggressive prostate cancer diagnosed 20 years ago, underscoring the value of longitudinal genomic profiling and advanced imaging to guide clinical decisions. After multiple treatment failures, genomic analyses of tissue and liquid biopsies revealed dynamic changes in tumor biology and the emergence of resistance mechanisms, particularly AR amplification, identified with a liquid biopsy test and validated by [

Indexed as

Biomarkers, TumorClinical Decision-MakingProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantBenzamidesDrug Resistance, NeoplasmHumansLiquid BiopsyMaleNeoplasm MetastasisNitrilesPhenylthiohydantoinReceptors, AndrogenBenzamidesBiomarkers, TumorenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenAR amplificationbipolar androgen therapy (BAT)liquid biopsylongitudinal genomic profilingmetastatic castration-resistant prostate cancer (mCRPC)tumor evolution

Identifiers

PMID40806723
PMCPMC12347661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.